These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16166320)

  • 1. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.
    Shafran A; Ifergan I; Bram E; Jansen G; Kathmann I; Peters GJ; Robey RW; Bates SE; Assaraf YG
    Cancer Res; 2005 Sep; 65(18):8414-22. PubMed ID: 16166320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
    Bram E; Ifergan I; Shafran A; Berman B; Jansen G; Assaraf YG
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):826-34. PubMed ID: 16612649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.
    Chen ZS; Robey RW; Belinsky MG; Shchaveleva I; Ren XQ; Sugimoto Y; Ross DD; Bates SE; Kruh GD
    Cancer Res; 2003 Jul; 63(14):4048-54. PubMed ID: 12874005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
    Assaraf YG
    Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
    Volk EL; Schneider E
    Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
    Ozvegy-Laczka C; Köblös G; Sarkadi B; Váradi A
    Biochim Biophys Acta; 2005 Feb; 1668(1):53-63. PubMed ID: 15670731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates.
    Wielinga P; Hooijberg JH; Gunnarsdottir S; Kathmann I; Reid G; Zelcer N; van der Born K; de Haas M; van der Heijden I; Kaspers G; Wijnholds J; Jansen G; Peters G; Borst P
    Cancer Res; 2005 May; 65(10):4425-30. PubMed ID: 15899835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport.
    Mitomo H; Kato R; Ito A; Kasamatsu S; Ikegami Y; Kii I; Kudo A; Kobatake E; Sumino Y; Ishikawa T
    Biochem J; 2003 Aug; 373(Pt 3):767-74. PubMed ID: 12741957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.
    Rhee MS; Schneider E
    Biochem Pharmacol; 2005 Jan; 69(1):123-32. PubMed ID: 15588721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
    Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
    Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
    Breedveld P; Pluim D; Cipriani G; Dahlhaus F; van Eijndhoven MA; de Wolf CJ; Kuil A; Beijnen JH; Scheffer GL; Jansen G; Borst P; Schellens JH
    Mol Pharmacol; 2007 Jan; 71(1):240-9. PubMed ID: 17032904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport.
    Hou YX; Li CZ; Palaniyandi K; Magtibay PM; Homolya L; Sarkadi B; Chang XB
    Biochemistry; 2009 Sep; 48(38):9122-31. PubMed ID: 19691360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.
    Hooijberg JH; Broxterman HJ; Kool M; Assaraf YG; Peters GJ; Noordhuis P; Scheper RJ; Borst P; Pinedo HM; Jansen G
    Cancer Res; 1999 Jun; 59(11):2532-5. PubMed ID: 10363967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines.
    Rothem L; Ifergan I; Kaufman Y; Priest DG; Jansen G; Assaraf YG
    Biochem J; 2002 Nov; 367(Pt 3):741-50. PubMed ID: 12139489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
    Henriksen U; Gether U; Litman T
    J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
    Ahmed-Belkacem A; Pozza A; Muñoz-Martínez F; Bates SE; Castanys S; Gamarro F; Di Pietro A; Pérez-Victoria JM
    Cancer Res; 2005 Jun; 65(11):4852-60. PubMed ID: 15930306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
    Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
    Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.